Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Investigation of sialic acids and sialyltransferase activity in blood of patients with systemic scleroderma.

Gabrielyan ND, Komleva AV, Nasonov VV, Alekperov RT, Starovoitova MN, Guseva NG.

Biochemistry (Mosc). 1999 May;64(5):561-4.

PMID:
10381618
2.
3.

Diagnostic significance of nailfold bleeding in scleroderma spectrum disorders.

Sato S, Takehara K, Soma Y, Tsuchida T, Ishibashi Y.

J Am Acad Dermatol. 1993 Feb;28(2 Pt 1):198-203.

PMID:
8432916
4.

The metabolism of sialic acid in cystic fibrosis.

Ben-Yoseph Y, Defranco CL, Nadler HL.

Pediatr Res. 1981 May;15(5):839-42.

PMID:
7243384
5.

Clinical evaluation of scleroderma spectrum disorders using a points system.

Ihn H, Sato S, Tamaki T, Soma Y, Tsuchida T, Ishibashi Y, Takehara K.

Arch Dermatol Res. 1992;284(7):391-5.

PMID:
1288419
6.

Altered behaviour of erythrocytes in scleroderma.

Kovacs IB, Sowemimo-Coker SO, Kirby JD, Turner P.

Clin Sci (Lond). 1983 Nov;65(5):515-9.

PMID:
6617097
7.

Sialic acid content and sialyltransferase activity in lymphocytes from neonates.

Komlos L, Levinsky H, Goldman J, Peleg D, Halbrecht I, Allalouf D.

Biol Neonate. 1988;54(5):270-4.

PMID:
3203121
8.

Sialyltransferase levels and sialic acid concentrations in sera of patients with malignant melanomas.

Herrmann WP, Gielen W.

Arch Dermatol Res. 1979 Jul 30;265(3):321-9.

PMID:
475455
9.

Low plasma protein nitrotyrosine levels distinguish primary Raynaud's phenomenon from scleroderma.

Kingdon EJ, Mani AR, Frost MT, Denton CP, Powis SH, Black CM, Moore KP.

Ann Rheum Dis. 2006 Jul;65(7):952-4. Epub 2005 Nov 24.

10.

Evaluation of serum sialic acid, sialyltransferase and sialoproteins in oral cavity cancer.

Raval GN, Patel DD, Parekh LJ, Patel JB, Shah MH, Patel PS.

Oral Dis. 2003 May;9(3):119-28.

PMID:
12945593
11.

Antibodies to centromere and centriole in scleroderma spectrum disorders.

Sato S, Fujimoto M, Ihn H, Takehara K.

Dermatology. 1994;189(1):23-6.

PMID:
8003781
12.

Sialic acid content and sialyltransferase activity in human lymphocytes with advancing age.

Allalouf D, Komlos L, Notmann J, Halbrecht I, Levinsky H.

Mech Ageing Dev. 1988 Jul;44(1):45-50.

PMID:
3205063
13.

Immunosuppression, sialic acid, and sialyltransferase of neonatal and maternal bovine serum.

Sherblom AP, Smagula RM, Moody CE, Anderson GW.

J Reprod Immunol. 1986 Dec;9(4):365-75.

PMID:
3820192
14.

[Clinical significant of sialic acid concentrations in the serum of melanoma patients].

Hermann WP, Gielen W.

Hautarzt. 1980 Apr;31(4):184-7. German.

PMID:
7399910
15.

[The mechanisms of intravascular blood coagulation in patients with systemic scleroderma].

Diubanova GA, Sidorova LD, Barkagan LZ, Movchan EA, Valentik MF.

Ter Arkh. 1990;62(5):63-6. Russian.

PMID:
2396220
17.

Increased urinary pyridinoline cross-link compounds of collagen in patients with systemic sclerosis and Raynaud's phenomenon.

Istok R, Czirják L, Lukác J, Stancíková M, Rovenský J.

Rheumatology (Oxford). 2001 Feb;40(2):140-6.

PMID:
11257149
18.

Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls.

Young-Min SA, Beeton C, Laughton R, Plumpton T, Bartram S, Murphy G, Black C, Cawston TE.

Ann Rheum Dis. 2001 Sep;60(9):846-51.

19.

Cell surface sialylation and ecto-sialyltransferase activity of human CD34 progenitors from peripheral blood and bone marrow.

Schwartz-Albiez R, Merling A, Martin S, Haas R, Gross HJ.

Glycoconj J. 2004;21(8-9):451-9.

PMID:
15750786
20.

[The total proteolytic and collagenolytic activity in the blood cells of patients with systemic scleroderma].

Solov'eva NI, Volkova ZI, Shcherbakov AB.

Ter Arkh. 1991;63(12):88-92. Russian.

PMID:
1666462

Supplemental Content

Support Center